CGTX
Income statement / Annual
Last year (2025), Cognition Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Cognition Therapeutics Inc's net income was -$23.49 M.
See Cognition Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$235.00 K
|
$0.00
|
$98.00 K
|
$81.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$235.00 K
|
$0.00
|
-$98.00 K
|
-$81.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$37.19 M
|
$41.68 M
|
$37.20 M
|
$30.32 M
|
$18.57 M
|
$12.89 M
|
$14.38 M
|
| General & Administrative Expenses |
$10.61 M
|
$12.29 M
|
$13.53 M
|
$13.23 M
|
$10.03 M
|
$4.52 M
|
$3.45 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.61 M
|
$12.29 M
|
$13.53 M
|
$13.23 M
|
$10.03 M
|
$4.52 M
|
$3.45 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$235.00 K
|
$0.00
|
-$98.00 K
|
-$13.16 M
|
| Operating Expenses |
$47.80 M
|
$53.97 M
|
$50.72 M
|
$43.32 M
|
$28.60 M
|
$17.31 M
|
$4.67 M
|
| Cost And Expenses |
$47.80 M
|
$53.97 M
|
$50.72 M
|
$43.55 M
|
$28.60 M
|
$17.41 M
|
$4.67 M
|
| Interest Income |
$0.00
|
$0.00
|
$27.00 K
|
$22.22 M
|
$17.45 M
|
$10.86 M
|
$13.16 M
|
| Interest Expense |
$13.00 K
|
$25.00 K
|
$0.00
|
$28.00 K
|
$893.00 K
|
$1.75 M
|
$1.02 M
|
| Depreciation & Amortization |
$228.00 K
|
$266.00 K
|
$252.00 K
|
$235.00 K
|
$93.00 K
|
$98.00 K
|
$81.00 K
|
| EBITDA |
-$23.25 M |
-$33.68 M |
-$25.51 M |
-$21.13 M |
-$10.73 M |
-$5.99 M |
-$3.74 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$24.31 M
|
$20.00 M
|
$24.94 M
|
$22.15 M
|
$16.88 M
|
$9.57 M
|
$0.00
|
| Income Before Tax |
-$23.49 M
|
-$33.97 M
|
-$25.79 M
|
-$21.40 M
|
-$11.72 M
|
-$7.84 M
|
-$4.84 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$22.15 M
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$23.49 M
|
-$33.97 M
|
-$25.79 M
|
$757.00 K
|
-$11.72 M
|
-$10.07 M
|
-$6.95 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.32 |
-0.85 |
-0.86 |
-0.74 |
-0.73 |
-0.55 |
-0.32 |
| EPS Diluted |
-0.32 |
-0.85 |
-0.86 |
-0.74 |
-0.73 |
-0.55 |
-0.32 |
| Weighted Average Shares Out |
$72.77 M
|
$39.73 M
|
$29.99 M
|
$28.99 M
|
$22.23 M
|
$21.94 M
|
$21.94 M
|
| Weighted Average Shares Out Diluted |
$72.77 M
|
$39.73 M
|
$30.03 M
|
$28.99 M
|
$22.23 M
|
$21.94 M
|
$21.94 M
|
| Link |
|
|
|
|
|
|
|
